361 Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

361 Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-96,096	Closed	-$1.88M	–	452
2018 Q3	$1.88M	Buy	96,096 +431	+0.5%	+$8.19K	0.41%	76
2018 Q2	$1.58M	Sell	95,665 -10,496	-10%	-$160K	0.36%	151
2018 Q1	$1.51M	Buy	+106,161	New	+$1.57M	0.37%	117

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

361 Capital's HZNP Position: Q4 2018 in Review

361 Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2018, closing a stake of 96,096 shares — an estimated $1.88M sold.

361 Capital first reported a position in HZNP in Q1 2018 and held it in 3 quarters. The position peaked at $1.88M in Q3 2018. 239 funds tracked by Wall St. Rank hold HZNP as of Q4 2018.

361 Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2018 after selling out during the quarter.
361 Capital sold 96,096 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2018, an estimated $1.88M.
361 Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2018 and held it in 3 quarters.
361 Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.88M in Q3 2018.
239 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2018.

Based on 361 Capital's 13F filing for Q4 2018, filed 8 Feb 2019.